Company News »

Aradigm Announces Third Quarter 2014 Financial Results

Business Wire
Share on StockTwits
Published on

Aradigm Corporation (Nasdaq:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2014.

Total revenue was approximately $6.6 million for the third quarter of 2014 compared with revenue of approximately $4.6 million for the third quarter of 2013. Revenue for both periods consisted primarily of revenue from the Grifols collaboration arrangement as the Company is being reimbursed for Pulmaquin(R) inhaled ciprofloxacin project-related costs.

The Company’s net loss for the third quarter of 2014 was approximately $0.9 million, or $0.06 per share, compared with a net loss of approximately $14.9 million, or $1.59 per share, for the third quarter of 2013. The net loss in 2013 resulted primarily from the one-time, non-cash collaboration arrangement acquisition cost associated with the Grifols collaboration agreement. Total operating expenses for the third quarter of 2014 were approximately $7.5 million, compared with total operating expenses of approximately $19.0 million for the third quarter of 2013. In the third quarter of 2013, the Company recorded $15.9 million as a one-time, non-cash collaboration arrangement acquisition cost resulting from the Grifols collaboration agreement. The increase in other operating expenses was primarily due to higher R&D expenses from the Pulmaquin Phase III clinical trials which resulted in higher clinical trial expenses compared to the prior year period.

As of September 30, 2014, cash and cash equivalents totaled approximately $48.5 million.

“We are very pleased that, as a result of the FDA’s initiatives to accelerate the development of qualified anti-infective drugs, in the third quarter of 2014 we were granted Fast Track Designation to develop our investigational drug, Pulmaquin, for patients in need. Despite enormous progress in medicine, severe infections are a growing problem in our society. This is exemplified by the unmet medical need for effective therapies in non-cystic fibrosis bronchiectasis patients with chronic infections with Pseudomonas aeruginosa. This orphan condition is associated with frequent pulmonary exacerbations, poor quality of life and reduced life expectancy,” said Dr. Juergen Froehlich, Chief Medical Officer of Aradigm.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates under development for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE), cystic fibrosis and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. Aradigm is also developing Pulmaquin and a liposomal ciprofloxacin formulation as potential medications for patients with chronic lung infections with non-tuberculous mycobacteria (NTM), and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, Q fever and inhaled anthrax.

Aradigm has been granted orphan drug designations for liposomal ciprofloxacin as well as for ciprofloxacin for inhalation for non-CF BE in the U.S. In addition, the U.S. Food and Drug Administration (FDA) has designated Pulmaquin as a Qualified Infectious Disease Product (QIDP). The QIDP designation is granted for treatment of non-CF BE patients with chronic lung infections with Pseudomonas aeruginosa. The QIDP designation made Pulmaquin eligible for Fast Track designation which was granted by the FDA in September 2014.

More information about Aradigm can be found at

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including those related to the ORBIT-3 and ORBIT-4 clinical trials, as well as the other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 13, 2014, and the Company’s Quarterly Reports on Form 10-Q.

Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of Aradigm Corporation.



(In thousands, except per share data)


Three months ended Nine months ended
September 30, September 30,
2014 2013 2014 2013
Contract revenue – related party $ 6,573 $ 4,301 $ 24,988 $ 4,301
Grant revenue 44 305
Royalty revenue 251 200 778
Total revenue 6,617 4,552 25,493 5,079
Operating expenses:
Research and development 6,047 1,593 23,499 5,000
General and administrative 1,443 1,463 5,025 3,801
Collaboration arrangement acquisition cost 15,943 15,943
Restructuring and asset impairment 4 7 15 21
Total operating expenses 7,494 19,006 28,539 24,765
Loss from operations (877 ) (14,454 ) (3,046 ) (19,686 )
Interest income 5 1 8 4
Interest expense (421 ) (288 ) (1,222 )
Other income (expense), net (42 ) (55 ) (5 )
Gain on assignment of royalty interests 5,823
Gain from extinguishment of debt 3,041
Net income (loss) $ (914 ) $ (14,874 ) $ 5,483 $ (20,909 )
Change in unrealized gains (losses) on available-for-sale securities
Comprehensive income (loss) $ (914 ) $ (14,874 ) $ 5,483 $ (20,909 )
Basic and diluted net income (loss) per common share $ ( 0.06 ) $ (1.59 ) $ 0.37 $ (2.87 )
Shares used in computing basic net income (loss) per common share 14,706 9,353 14,691 7,298
Shares used in computing diluted net income (loss) per common share 14,706 9,353 14,722 7,298



(In thousands)

September 30, December 31,
2014 2013
(Unaudited) *
Current assets:
Cash and cash equivalents $ 48,492 $ 48,131
Restricted cash 250
Receivables 91 92
Prepaid and other current assets 972 1,448
Total current assets 49,805 49,671
Property and equipment, net 582 400
Other assets 2,966 353
Total assets $ 53,353 $ 50,424
Current liabilities:
Accounts payable $ 1,432 $ 619
Accrued clinical and cost of other studies 1,669 1,831
Accrued compensation 833 198
Deferred revenue 1,172 4,379
Facility lease exit obligation 187 168
Other accrued liabilities 247 82
Total current liabilities 5,540 7,277
Deferred rent 108 132
Facility lease exit obligation, non-current 153 297
Deferred revenue, long term 7,839
Note payable, net of discount and accrued interest 9,035
Shareholders’ equity 39,713 33,683
Total liabilities and shareholders’ equity $ 53,353 $ 50,424

* The balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.

Share on StockTwits